Skip to main content
OpenTrials
Completed

NCT Number: NCT02199795

Functional Electrical Stimulation Mediated Neuroplasticity: Lower Extremity CCNMES in Stroke

This is a small pilot randomized controlled trial which will enroll both subacute (<6 mos) and chronic (>6 mos) stroke survivors with ankle dorsiflexion weakness. The subjects will be randomized to Contralaterally Controlled Neuromuscular Electrical Stimulation (CCNMES) versus control. The primary objective of this study is to compare the effect of 6-weeks of lower extremity CCNMES, applied in an anti-phase application, on motor impairment and functional mobility to a control group.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Stroke Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Footdrop Hemiparesis Hemiplegia Mononeuropathies Nervous System Diseases Neurologic Manifestations Neuromuscular Diseases Paralysis Paresis Pathological Conditions, Signs and Symptoms Peripheral Nervous System Diseases Peroneal Neuropathies Signs and Symptoms Vascular Diseases

Age range

21 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

MetroHealth Medical Center

Cleveland, Ohio, 44109, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 21 to 75 years
  • Minimum of 2 wks from a first clinical non-hemorrhagic or hemorrhagic stroke
  • Medically stable
  • Unilateral lower extremity hemiparesis
  • Ankle dorsiflexor strength of ≤4/5 on the Medical Research Council scale, while seated
  • NMES of the paretic ankle dorsiflexors produces ankle dorsiflexion to neutral without pain.
  • Full voluntary ROM of the contralateral ankle
  • Skin intact on bilateral lower extremities
  • Able to don the NMES system or caregiver available to assist with device if needed.
  • Able to hear and respond to stimulator auditory cues
  • Able to follow 3-stage commands
  • Able to recall 2 of 3 items after 30 minutes
  • Cognition and communication adequate for safe use of the device based on neurological assessment by physician principal investigator

Exclusion criteria

  • Severely impaired cognition and communication
  • History of peroneal nerve injury
  • History of Parkinson's, spinal cord injury, traumatic brain injury, or multiple sclerosis
  • Uncontrolled seizure disorder
  • Uncompensated hemi-neglect (extinguishing to double simultaneous stimulation)
  • Edema of the paretic lower extremity
  • Absent sensation of paretic lower extremity
  • Evidence of deep venous thrombosis or thromboembolism
  • History of cardiac arrhythmias with hemodynamic instability
  • Cardiac pacemaker or other implanted electronic system
  • Botulinum toxin injections to any lower extremity muscle in the last 3 months
  • Pregnancy
  • Symptomatic peripheral neuropathy
  • Current use of psychoactive medications (except selective serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor antidepressants)
  • Acetylcholinesterase inhibitor usage
  • Unstable asthmatic condition
  • Metallic implants (including clips and/or wires)
  • Prosthetic heart valves
  • Cardiac, renal or other stent
  • History of claustrophobia
  • Low visual acuity
  • Body weight or body habitus not compatible to MRI machine
  • Medical, psychological, or social concern identified by the principal investigator or co-investigator which suggests inappropriateness of subject participation

Treatment and study plan

Contralaterally Controlled Neuromuscular Electrical Stimulation

Device

Cyclic Neuromuscular Electrical Stimulation

Device

Primary outcomes

  1. Change in Lower Extremity Fugl-Meyer Score at End of Treatment

    Time frame: Baseline and End of Treatment (6 weeks)

    The Lower Extremity Fugl-Meyer (LEFM) Assessment is a measure of lower limb motor impairment. Participants are asked to attempt to perform a list of isolated and simultaneous movements of the hip, knee, and ankle that take into account synergy patterns, isolated strength, coordination, and hypertonia. Each movement attempt is graded on a 3-point ordinal scale (0, cannot perform; 1, perform partially; and 2, perform fully) and these subscores are summed to provide a maximum score of 34, minimum score of 0 (i.e., full scale range 0-34).

    Higher scores are considered to be a better outcome. For each individual, the score prior to treatment was subtracted from the score at end of the 6-week treatment. Then for each treatment group, these change scores were averaged.

Secondary outcomes

  1. Change in 10-Meter Walk Test

    Time frame: Baseline and End of Treatment (6 weeks)

    Time to walk 10 m was measured using a stop-watch. For each individual, the time to walk 10 m prior to treatment was subtracted from the time to walk 10 m at end of the 6-week treatment. Then for each treatment group, these changes in time were averaged.

  2. Change in Ankle Movement Tracking Error at End of Treatment

    Time frame: Baseline and End of Treatment (6 weeks)

    Ankle dorsiflexion angle was measured continuously using an electrogoniometer. The subject was seated in front of a computer screen which displayed a 30-sec long sine-wave trace scrolling right to left across the screen. The peak to peak amplitude of the sine wave was set equal to the participant's achievable active range of ankle movement and put on a scale of 0 to 100. Three 30-sec trials were run in which the participant's task was to trace the sine wave by moving their paretic ankle. Error was calculated as the average vertical distance between the sine wave and the ankle angle. The lowest error across three trials was taken as the error for that time point.

    Lower errors are considered to be better outcomes.

    For each participant, the error prior to treatment was subtracted from the error at end of the 6-week treatment. Then for each treatment group, these change scores were averaged. A negative change in error scores is considered an improvement.

  3. Change in Modified Emory Functional Ambulation Profile (MEFAP) at End of Treatment

    Time frame: Baseline and End of Treatment (6 weeks)

    The MEFAP is a measure of functional ambulation, measuring the time to ambulate through 5 common environmental terrains: 1) 5-meter walk on a hard floor, 2) 5-meter walk on a carpeted floor, 3) rise from a chair, 3-meter walk, return to seated position, 4) standardized obstacle course (bricks to step over), 5) stair ascent and descent. The five times subscores were added to derive a total time.

    Lower times are considered to be a better outcome.

    For each individual, the MEFAP completion time prior to treatment was subtracted from the MEFAP completion time at end of the 6-week treatment. Then for each treatment group, these change values were averaged.

Sponsors and collaborators

Lead sponsor

MetroHealth Medical Center

Other

Collaborators

  • Case Western Reserve University
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Registry information

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Jul 24, 2014
Registry last updated
Nov 8, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.